Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5696989 | 0.91 | SCD (0.62) | MMP13SCD | |
| SCHEMBL5696824 | 0.87 | MMP13 (0.63) | MMP13SCD | |
| SCHEMBL5697045 | 0.84 | MMP13 (0.46) | MMP13 | |
| SCHEMBL5697040 | 0.83 | MMP13 (0.69) | MMP13SCD | |
| SCHEMBL5696979 | 0.82 | MMP13 (0.59) | MMP13 | |
| SCHEMBL6427533 | 0.79 | MMP13 (0.82) | MMP13 | |
| SCHEMBL2315861 | 0.79 | SCD (0.82) | SCD | |
| SCHEMBL3853612 | 0.78 | SCD (0.70) | SCD | |
| SCHEMBL5696971 | 0.77 | MMP13 (0.65) | MMP13 | |
| SCHEMBL5922977 | 0.77 | MMP13 (0.56) | MMP13SCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1587516-A1 | AMIDE AND ESTER MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2005-10-26 | — | — | EP | claimed |
| WO-2004064842-A1 | AMIDE AND ESTER MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-08-05 | — | — | WO | claimed |
| US-20040142950-A1 | Amide and ester matrix metalloproteinase inhibitors | BUNKER AMY MAE (US) | 2004-07-22 | — | — | US | claimed |
| US-20060247231-A1 | Amide and ester matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY LLC | 2006-11-02 | — | — | US | disclosed |
| EP-1680125-A1 | COMBINATION OF AN ALLOSTERIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 AND A LIGAND TO AN ALPHA-2-DELTA RECEPTOR | Warner-Lambert Company LLC (US) | 2006-07-19 | — | — | EP | disclosed |
| EP-1587516-A1 | AMIDE AND ESTER MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2005-10-26 | — | — | EP | disclosed |
| WO-2005002585-A1 | COMBINATION OF AN ALLOSTERIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 AND A LIGAND TO AN ALPHA-2-DELTA RECEPTOR | WARNER-LAMBERT COMPANY LLC (US) | 2005-01-13 | — | — | WO | disclosed |
| US-20050004177-A1 | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor | WARNER-LAMBERT COMPANY LLC | 2005-01-06 | — | — | US | disclosed |
| WO-2004064842-A1 | AMIDE AND ESTER MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-08-05 | — | — | WO | disclosed |
| US-20040142950-A1 | Amide and ester matrix metalloproteinase inhibitors | BUNKER AMY MAE (US) | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247231-A1 | Amide and ester matrix metalloproteinase inhibitors | MMP13, MMP9, MMP3 | MMP13 1/4885SCD 465/4885 |
| US-20050004177-A1 | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor | MMP13, MMP10, MMP11 | MMP13 1/4885SCD 2320/4885 |
| US-20040142950-A1 | Amide and ester matrix metalloproteinase inhibitors | MMP13, MMP11, MMP9 | MMP13 1/4885SCD 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.